Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery

作者：Volak Adrienn; LeRoy Stanley G; Natasan Jeya Shree; Park David J; Cheah Pike See; Maus Andreas; Fitzpatrick Zachary; Hudry Eloise; Pinkham Kelsey; Gandhi Sheetal; Hyman Bradley T; Mu Dakai; Guhasarkar Dwijit; Stemmer Rachamimov Anat O; Sena Esteves Miguel; Badr Christian E^*; Maguire Casey A^*

来源：Journal of Neuro-Oncology, 2018, 139(2): 293-305.

DOI：10.1007/s11060-018-2889-2

• Adeno-associated virus vectors
• AAV
• Glioblastoma
• Glioma
• Cancer gene therapy
• Tumor stroma
• Reactive astrocytes
• Tumor-associated myeloid-derived cells

The malignant primary brain tumor, glioblastoma (GBM) is generally incurable. New approaches are desperately needed. Adeno-associated virus (AAV) vector-mediated delivery of anti-tumor transgenes is a promising strategy, however direct injection leads to focal transgene spread in tumor and rapid tumor division dilutes out the extra-chromosomal AAV genome, limiting duration of transgene expression. Intravenous (IV) injection gives widespread distribution of AAV in normal brain, however poor transgene expression in tumor, and high expression in non-target cells which may lead to ineffective therapy and high toxicity, respectively. Delivery of transgenes encoding secreted, anti-tumor proteins to tumor stromal cells may provide a more stable and localized reservoir of therapy as they are more differentiated than fast-dividing tumor cells. Reactive astrocytes and tumor-associated macrophage/microglia (TAMs) are stromal cells that comprise a large portion of the tumor mass and are associated with tumorigenesis. In mouse models of GBM, we used IV delivery of exosome-associated AAV vectors driving green fluorescent protein expression by specific promoters (NF-kappa B-responsive promoter and a truncated glial fibrillary acidic protein promoter), to obtain targeted transduction of TAMs and reactive astrocytes, respectively, while avoiding transgene expression in the periphery. We used our approach to express the potent, yet toxic anti-tumor cytokine, interferon beta, in tumor stroma of a mouse model of GBM, and achieved a modest, yet significant enhancement in survival compared to controls. Noninvasive genetic modification of tumor microenvironment represents a promising approach for therapy against cancers. Additionally, the vectors described here may facilitate basic research in the study of tumor stromal cells in situ.
[GRAPHICS]

• 出版日期2018-9